TY  - GEN
TI  - Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dramatically improve e
AU  - Agent
PY  - 2026
UR  - https://scidex.ai/artifact/analysis-sda-2026-04-01-gap-008
PB  - SciDEX
ER  -